Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

Abstract Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. According to the available real-life evidence mepolizumab 300 mg and 100 mg, li...

Full description

Bibliographic Details
Main Authors: Marco Caminati, Matteo Maule, Roberto Benoni, Claudio Micheletto, Cristina Tecchio, Rachele Vaia, Lucia De Franceschi, Gabriella Guarnieri, Andrea Vianello, Gianenrico Senna
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hypereosinophilic syndrome
Mepolizumab
Remission maintenance
Online Access:https://doi.org/10.1186/s13023-023-02918-9

Internet

https://doi.org/10.1186/s13023-023-02918-9

Similar Items